Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02730468
Recruitment Status : Completed
First Posted : April 6, 2016
Last Update Posted : October 27, 2017
Sponsor:
Collaborator:
Stanford University
Information provided by (Responsible Party):
Karius, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.

Condition or disease
Sepsis

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 350 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay
Study Start Date : April 2016
Actual Primary Completion Date : September 2017
Actual Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Accuracy of sequencing assay in diagnosing etiology of sepsis [ Time Frame: 7 days ]

Biospecimen Retention:   Samples With DNA
Plasma

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Subjects will be at least 18 years of age and who present to the Emergency Department with the diagnosis of sepsis
Criteria

Inclusion Criteria:

  1. 18 years or older

  2. Meet 2 of 4 sepsis criteria

    1. Temperature > 38C or < 36C
    2. Heart rate > 90 bpm
    3. Respiratory rate >20 or PaCO2 <32mmHg
    4. WBC >12000/µL or < 4000/µL or > 10% bands

Exclusion Criteria:

  1. Inability to understand instructions and comply with study-related procedures
  2. Any condition that in the opinion of the treating physician will prevent the subject from completing the study.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02730468


Locations
Layout table for location information
United States, California
Stanford University Hospital
Stanford, California, United States, 94305
Sponsors and Collaborators
Karius, Inc.
Stanford University
Investigators
Layout table for investigator information
Principal Investigator: Samuel Yang, MD Stanford University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Karius, Inc.
ClinicalTrials.gov Identifier: NCT02730468    
Other Study ID Numbers: 001-CL-01
First Posted: April 6, 2016    Key Record Dates
Last Update Posted: October 27, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Communicable Diseases
Infection
 Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes